|
| (R)-10-(2,4,5-trifluorobenzyl)-3-(trifluoromethyl)-6,7,10,11-tetrahydro-[1,2,4]triazolo[3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione Basic information |
Product Name: | (R)-10-(2,4,5-trifluorobenzyl)-3-(trifluoromethyl)-6,7,10,11-tetrahydro-[1,2,4]triazolo[3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione | Synonyms: | Impurity FP-B;Sitagliptin Impurity 20;Sitagliptin-17;Sitagliptin FP Impurity B;(R)-10-(2,4,5-trifluorobenzyl)-3-(trifluoromethyl);Sitagliptin impurity 6/Sitagliptin FP Impurity B/Sitagliptin Triazecine Analog/10-(2,4,5-Trifluorobenzyl)-3-(trifluoromethyl)-6,7,10,11-tetrahydro [1,2,4] triazolo [3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione;1,2,4-Triazolo[3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione, 6,7,10,11-tetrahydro-3-(trifluoromethyl)-10-[(2,4,5-trifluorophenyl)methyl]-, (10R)-;(10R)?- 6,?7,?10,?11-?Tetrahydro-?3-?(trifluoromethyl)?-?10-?[(2,?4,?5-?trifluorophenyl)?methyl]?-1,?2,?4-?triazolo[3,?4-?c]?[1,?4,?7]?triazecine-?8,?12(5H,?9H)?-?dione | CAS: | 2088771-61-1 | MF: | C16H13F6N5O2 | MW: | 421.3 | EINECS: | | Product Categories: | | Mol File: | 2088771-61-1.mol | |
| (R)-10-(2,4,5-trifluorobenzyl)-3-(trifluoromethyl)-6,7,10,11-tetrahydro-[1,2,4]triazolo[3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione Chemical Properties |
Melting point | >189°C (dec.) | density | 1.67±0.1 g/cm3(Predicted) | storage temp. | -20°C Freezer, Under inert atmosphere | solubility | DMSO (Slightly), Methanol (Slightly) | pka | 12.02±0.40(Predicted) | form | Solid | color | White to Off-White |
| (R)-10-(2,4,5-trifluorobenzyl)-3-(trifluoromethyl)-6,7,10,11-tetrahydro-[1,2,4]triazolo[3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione Usage And Synthesis |
Uses | (10R)-Sitagliptin Triazecine Analog is related to the family of Sitagliptin compounds which has recently been approved for the therapy of type II diabetes. |
| (R)-10-(2,4,5-trifluorobenzyl)-3-(trifluoromethyl)-6,7,10,11-tetrahydro-[1,2,4]triazolo[3,4-c][1,4,7]triazecine-8,12(5H,9H)-dione Preparation Products And Raw materials |
|